(An Anti-Tumour agent)

About Geftinat

Geftinat is classified as targeted therapy which means to target the epidermal growth factor receptor tyrosine kinase inhibitor. Geftinat is a signal transduction inhibitor

Geftinat is the prescription medicine; it is given to the patients under the guidance of medical oncologist.

About Geftinat


Advanced or metastatic non-small cell lung cancer

Geftinat tablet is indicated only after failure of both platinum based and taxol based chemotherapies

Dosage regimens

Geftinat tablets are ideally used for metastatic non-small cell lung cancer;

The usual recommended dosage of Geftinat tablet is 250mg should be taken with or without food as once a day

Safety points

Safety points to be followed for Geftinat

If patient unable to administered, tablets should be dissolve in 4 to 8 ounces of plain non-carbonated water and drink immediately


Brand: Geftinat
Active component: Gefitinib
Strength: 250MG
Mfg: Natco pharma
Package: 30 tablets in a container
Category: Anti-neoplastic

For More Information

Dosage Modification

The dosage of the tablet Geftinat should be altered in case of; Elevation of Alt & AST Diarrhea, ocular disorders, skin reactions Acute onset or worsening pulmonary symptoms

In pediatric

The safety and efficacy of tablet Geftinat has not been established

Precautions and warning

While patient taking Geftinat tablet, Caution should be taken in the conditions like; Pulmonary toxicity, Hepatic toxicity, Dermatological toxicity, Gastrointestinal effects, Hepatotoxicity and Ocular toxicity

Geftinat side effects

>10% of patients get; Skin reaction, diarrhea, loss of appetite, vomiting, increased ALT 1-10% of patients occurred; Elevation of AST, stomatitis, conjunctivitis, blepharitis, dry eye, elevation of ALT, nail disorders, diarrhea, increased bilirubin levels, loss of appetite, interstitial lung disease <1% of patients have chance to get; Interstitial lung disease, hyperbillirubemia, stomatitis, corneal erosion, aberrant eyelash growth, nail disorders, gastrointestinal perforation, ocular keratitis, Erythema multiforme and dermatitis Bullous, fatal hepatoxicity Renal and urinary disorders: cystitis, hemorrhagic cystitis Skin and subcutaneous tissue disorders: cutaneous vasculitis


Geftinat works as

Geftinat tablets are anti-cancer medicine which involved in by prohibiting the epidermal growth factor receptor tyrosine kinase by binding to adenosine triphosphate binding region of the enzyme. The activity of EGFR tyrosine kinase is signal transduction to malignant cells Thus the activity of EGFR is inhibited and growth of cancer cells also prohibits

Body works for geftinat tablet as


Geftinat is slowly absorbed in the body after oral administration The mean bioavailability of the drug is 60% The peak plasma concentration of the drug Gefitinib is occur within 3-7 hours


Human plasma protein bound with Geftinat around 90% The volume of distribution is 1400L


The metabolism of the drug Gefitinib occurs majorly in liver. With the help of cytochrome isoenzymes CYP3A4 metabolism occurs


The routes of elimination of metabolites are through feces and urine Feces 86% Urine 4% The terminal half life time of Geftinat tablet is 48 hours


Geftinat contraindicated; If patient taking Geftinat tablet, they may have chance to get anaphylactic reactions

While using concomitant use of Geftinat tablets with other drugs causes some interaction

These are some drugs which will interfere with serum concentration of cytochrome isoenzymes H2 receptor antagonist and proton pump inhibitors: Combining with Geftinat, decrease the serum concentration of Gefitinib Geftinat elevates the anti-coagulant effect of vitamin K antagonist like warfarin Increase the serum concentration of CYP2D6 substrates while combining with Abiraterone Acetate Increase the serum concentration of CYP2D6 substrates with Ajmaline Depletes the serum concentration of Gefitinib with antacids Elevates the serum concentration of CYP3A4 substrates while combining with Aprepitant Some of the drugs like; Asunaprevir, Bosentan, Ceritinib, cobicistat, conivaptan, CYP2D6 inhibitors (moderate and strong), CYP3A4 inducers (moderate and strong), CYP3A4 inhibitors (moderate and strong), Dabrafenib, darunavir, dasatinib, deferasirox, Enzalutamide, fosaprepitant

Geftinat tablets should be stopped in some conditions;

Confirmed interstitial lung disease Persistent ulcerative keratitis Gastrointestinal perforation Severe hepatic impairment

Concomitant use with strong CYP3A4 inducers

Increase the dose of Geftinat to 500mg orally as a single dose if no adverse reaction produces Restart to 250mg orally as a single dose after discontinuation of CYP3A4 strong inducers

Geftinat use in pregnancy and lactation

Pregnancy category: C Geftinat should not be recommended in pregnancy condition, because it may cause fetal harm Breast feeding is also not recommended, the metabolites of Geftinat tablets are excreted in human milk. It transfer through milk to babies and cause harm

Storage condition

The storage condition of Geftinat tablet; Protect from direct sunlight Keep out of reach from children and animal Store in cool and dry place

Missed dose

If patient fail to take Geftinat tablet, they may get advice from medical practitioner (oncologist) for administration of the missed dose within the time Otherwise the missed dose should be skipped and follow the next dosing schedule Do not double the dose

Prescription is a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines. will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists

The drug information provided in the is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website. requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from is a Caregiver can order prescription medicines on your behalf.

This information should not be used to decide whether to take this product or any other medicine. Only the health care provider has the knowledge and training to determine which medications are appropriate for the particular patient. This information does not support any medication as safe, effective or approved for the treatment of any patient or condition health. This is just a brief overview of the general information about this product. It does NOT include all information about possible uses, directions, warnings, precautions, interactions, adverse effects or risks that may occur attitude to this product. This information is not a specific medical advice and does not replace the information you receive from the health care provider. you should talk with your health care provider for complete information about the risks and advantages of using this product.


   Portion 'A' First Floor,
Old No. 131, New No. 50,
Pedariyar Koil Street,
Seven Wells,
Chennai - 600001.